Page 4 - Thrombolysis May News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thrombolysis may. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thrombolysis May Today - Breaking & Trending Today

Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

January 29, 2021 2:45pm EST
Study has the potential to facilitate a filing for Emergency Use Authorization (EUA)
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP). ....

City Of , United Kingdom , Raul Rodriguez , Daiichi Sankyo , Jason Roos , Us Department Of Defense , Rigel Pharmaceuticals Inc , Program Executive Office For Chemical , Imperial College London , Nuclear Defense , Inova Health System , Joint Program Executive Office , Joint Program Executive Officer , Severe Acute Respiratory Syndrome , Rigel Pharmaceuticals , Imperial College , Englj Med , Thrombolysis May , Rxiv July , Hsiehs L , Pathogenic Host Factors , Acute Viral , Human Neutrophil Granulocytes , Immunology July , Health Sciences , Adverse Effects ,

Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
We are grateful to receive this funding from the DOD and for their demonstrated commitment towards finding safe and effective treatments for COVID-19 patients, said Raul Rodriguez, Rigel s president and CEO. These additional resources will contribute significantly to the advancement of our P ....

City Of , United Kingdom , Raul Rodriguez , Daiichi Sankyo , Jason Roos , Us Department Of Defense , Rigel Pharmaceuticals Inc , Program Executive Office For Chemical , Exchange Commission , Prnewswire Rigel Pharmaceuticals Inc , Imperial College London , Nuclear Defense , Inova Health System , Joint Program Executive Office , Joint Program Executive Officer , Severe Acute Respiratory Syndrome , Rigel Pharmaceuticals , Imperial College , Englj Med , Thrombolysis May , Rxiv July , Hsiehs L , Pathogenic Host Factors , Acute Viral , Human Neutrophil Granulocytes , Immunology July ,